CompletedPhase 1NCT01132586
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Studying Acute myeloid leukemia with t(9;11)(p22;q23)
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- William BlumOhio State University Comprehensive Cancer Center
- Intervention
- Lenalidomide(drug)
- Enrollment
- 61 enrolled
- Eligibility
- 18-64 years · All sexes
- Timeline
- 2010 – 2014
Study locations (1)
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01132586 on ClinicalTrials.gov